Вопросы современной педиатрии (Apr 2008)

COMPARISON OF CLINICAL ACTIVITY OF PIMECROLIMUS IN PEDIATRIC PATIENTS WITH MILD AND MODERATE ATOPIC DERMATITIS

  • E.V. Deeva,
  • L.M. Ogorodova,
  • I.A. Deev,
  • I.V. Sheveleva

Journal volume & issue
Vol. 7, no. 2
pp. 55 – 61

Abstract

Read online

Atopic dermatitis (ad) is prevalent disease in younger children. Calcium inhibitor pimecrolimus (elidel, cream 1%) is the latest anti-inflammatory drug offered for management of ad. The activity of pimecrolimus was evaluated in open, prospective, randomized, comparison trial, on 60 children (age from 3 months to 7 years) with mild and moderate ad. Pimecrolimus was more effective in management of mild ad on the assumption of regular use of drug (TIS < 17), and topical corticosteroids were effective in patients with moderate ad.Key words: children, atopic dermatitis, pimecrolimus, topical corticosteroids, management.